Single-Use Systems Enable Commercial-Scale CGT Manufacturing

Why It Matters

By streamlining production and mitigating supply risks, SUS accelerate patient access, lower therapy costs, and make commercial-scale CGT financially viable.

Key Takeaways

• Single-use systems cut cleaning validation, enable rapid changeover.
• Automation and modular platforms drive scale‑out for CGT.
• Supply‑chain risk mitigated by interchangeable parts and dual sourcing.
• Standardization lacking; industry seeks vendor‑independent connectors.
• Injection‑molded cassettes reduce cost, simplify distributed manufacturing.

Pulse Analysis

The shift toward single‑use technologies has reshaped the biomanufacturing landscape, especially for cell and gene therapies that demand sterility, flexibility, and rapid turnaround. Pre‑sterilized consumables remove the burdens of cleaning validation and allow manufacturers to switch between personalized batches with minimal downtime, a critical advantage for autologous treatments. As the CGT market moves from niche clinical trials to broader commercial deployment, the ability to maintain GMP compliance while scaling production becomes a decisive competitive factor.

Automation is the next frontier for SUS, turning manual, labor‑intensive steps into repeatable, closed processes. Modular platforms such as Cytiva’s Sefia and Cellular Origins’ robotic systems integrate single‑use kits with digital control, enabling scale‑out architectures where multiple small reactors operate in parallel. This approach not only improves throughput but also reduces capital expenditure compared with building single, massive vessels. Yet, without industry‑wide standards for connectors, materials, and validation protocols, interoperability remains a bottleneck, prompting firms to adopt vendor‑independent solutions and dual‑sourcing strategies to safeguard supply continuity.

Innovations like Trenchant BioSystems’ injection‑molded polycarbonate cassettes illustrate how design simplification can further lower costs and accelerate distributed manufacturing. By keeping cells stationary and delivering reagents via the cassette, the system cuts assembly complexity, shortens training cycles, and mitigates component shortages. Coupled with regionalized production networks, these advances promise to shrink lead times from weeks to days, expand patient access, and align with evolving regulatory expectations worldwide. As the ecosystem matures, standardization and robust supply‑chain practices will be essential to sustain the momentum of commercial‑scale CGT delivery.